• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity

    2/28/22 9:00:00 AM ET
    $HZNP
    $WLTW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Insurers
    Finance
    Get the next $HZNP alert in real time by email

    -- The new program and website are designed to create conversations that will lead to new resources to support diversity, equity, inclusion and allyship within the rare disease community --

    -- #RAREis webcast conversation with The Akari Foundation, Amigos Múltiplos, Child Neurology Foundation and The Sumaira Foundation to be held on Feb. 28 at 8:55 a.m. CT --

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced the launch of the #RAREis Representation program, which expands Horizon's #RAREis program to support advancing global equity in the rare disease community. The program is centered around a new section of the #RAREis website where individuals are invited to provide feedback via a short survey on key issues related to rare disease equity, which will be used to inform long-term programming, toolkits and resources for the rare disease community.

    The rare disease community comprises an estimated 400 million people worldwide living with a rare disease and millions more impacted as parents, siblings, extended family members, caregivers and friends. People living with rare diseases face many challenges, including access to diagnosis, appropriate care and approved treatments. For many in the community, barriers can impact their rare disease experience and their care based on the social determinants of health, among other factors. Throughout 2022, #RAREis will be sharing diverse stories, providing resources and hosting community conversations to drive action.

    "During the past several years Horizon has been engaging with the rare disease community to better understand the barriers people with rare diseases are facing when it comes to representation and inclusion," said Matt Flesch, vice president, communications and patient advocacy, Horizon Therapeutics.

    "We held a patient advocacy summit on diversity, equity and inclusion last year, and have been actively engaging and supporting organizations who are leading this work as part of our long-term commitment to addressing health inequalities. The #RAREis Representation program will gather additional feedback and insights directly from the global rare disease community that will help guide future programs that advance and improve inclusivity and equity in rare disease."

    Horizon will also be hosting a webinar on Rare Disease Day to foster conversation around advancing global equity. The global webinar, "#RAREis Representation: Discussing the Importance of Diversity, Equity, Inclusion and Allyship in the Global Rare Disease Community," will be moderated by Vikram Karnani, executive vice president, president international, Horizon Therapeutics and will discuss diversity, equity, inclusion and allyship within the rare disease community. Registration for the webinar is available here.

    "Living with a rare disease can be an isolating experience, especially when you come from a diverse background," said Sumaira Ahmed, founder and executive director, The Sumaira Foundation. "It's imperative that communities of color are represented and the issues impacting diverse groups are a part of the conversation around rare disease equity. I'm excited to shine a light on the need for greater inclusion in the rare disease community."

    Rare Disease Day Community Support

    Horizon is also engaging with the rare disease community through global Rare Disease Day awareness efforts. Horizon is the title sponsor for Rare Disease Week on Capitol Hill, hosted by the EveryLife Foundation for Rare Diseases. Horizon will co-sponsor a panel with Rare Disease Diversity Coalition partners along with the Black Women's Health Imperative around the importance of knowing your family's history around rare disease. Horizon has sponsored Rare Diseases Ireland's Raise A Toastie campaign to raise awareness for those living with a rare disease in Ireland.

    As a further sign of support for the rare disease community, Horizon's U.S. headquarters in Deerfield, Illinois and global headquarters in Dublin, Ireland will be lit in pink, purple, green and blue, the official colors of Rare Disease Day. The Chicago Cubs will also call attention to Rare Disease Day by lighting Gallagher Way in Rare Disease Day colors and through messaging on the Wrigley Field Marquee. And, in partnership with Willis Towers Watson (NASDAQ:WLTW) and Willis Tower, the Willis Tower antennas in Chicago will also be lit in pink and purple to signify Horizon's commitment to the rare disease community.

    This new #RAREis Representation programming is in addition to continued support for other rare disease programming supporting rare disease equity by Horizon through its #RAREis program, such as the #RAREis Scholarship Fund and the #RAREis Adoption Fund.

    About Rare Disease Day

    Rare Disease Day is marked globally every year on the last day of February to underscore the nature of rare diseases and what patients face. The National Organization for Rare Disorders (NORD) is the sponsor of Rare Disease Day in the United States. For more information about Rare Disease Day in the U.S., go to rarediseaseday.us. For information about global activities, go to rarediseaseday.org. To search for information about rare diseases, visit NORD's website, rarediseases.org.

    About Willis Tower

    Located at 233 S. Wacker Drive in the heart of downtown Chicago, Willis Tower is an urban destination and state-of-the-art workplace that welcomes prominent businesses ranging from law firms to large airline corporations to insurance companies. Standing 1,450 feet and 110 stories tall, Willis Tower has the region's most breathtaking views of Chicago and Lake Michigan. Willis Tower's Skydeck attracts more than 1.7 million visitors each year with its inviting hospitality and memorable experiences. In early 2017, Blackstone and EQ Office announced plans for the biggest restorative transformation project in the building's 47-year history. The renovation project now underway includes the addition of Catalog, a more than 300,000 square-feet curated dining, entertainment and community experience, as well as a 30,000 square-feet outdoor terrace, evolving at the base of the tower.

    About #RAREis

    In February of 2017, Horizon launched the #RAREis program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The program is anchored by an Instagram page and website that showcases photos and stories of people touched by rare disease and captures elements of their patient, caregiver or advocate experience. To learn more, visit the #RAREis Instagram and Facebook page and visit the website at www.RAREisCommunity.com.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005315/en/

    Get the next $HZNP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HZNP
    $WLTW

    CompanyDatePrice TargetRatingAnalyst
    Horizon Therapeutics Public Limited Company
    $HZNP
    11/1/2022$74.00Neutral
    H.C. Wainwright
    Horizon Therapeutics Public Limited Company
    $HZNP
    8/4/2022Outperform → Mkt Perform
    SVB Leerink
    Horizon Therapeutics Public Limited Company
    $HZNP
    6/14/2022$139.00Buy
    UBS
    Horizon Therapeutics Public Limited Company
    $HZNP
    6/6/2022$95.00Mkt Perform
    SVB Leerink
    Horizon Therapeutics Public Limited Company
    $HZNP
    5/23/2022$95.00Mkt Perform
    SVB Leerink
    Horizon Therapeutics Public Limited Company
    $HZNP
    3/15/2022$140.00Outperform
    Oppenheimer
    Horizon Therapeutics Public Limited Company
    $HZNP
    3/2/2022$135.00 → $140.00Overweight
    Morgan Stanley
    Willis Towers Watson Public Limited Company
    $WLTW
    1/4/2022$280.00 → $284.00Overweight
    Wells Fargo
    More analyst ratings

    $HZNP
    $WLTW
    Leadership Updates

    Live Leadership Updates

    See more
    • ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

      LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D

      1/11/22 7:45:00 AM ET
      $ABBV
      $ABT
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Willis Towers Watson appoints new Canada Leader

      TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Willis Towers Watson (NASDAQ:WLTW), a leading global advisory, broking and solutions company, today announced the appointment of Laura Samaroo as the Region Leader for Canada. Most recently the Market Leader for Western Canada, Samaroo has been with Willis Towers Watson for over thirty years, with leadership roles in both management and consulting. In her new role, Samaroo will continue to focus on strengthening client relationships, providing strategic guidance to support business development, and promoting Willis Towers Watson's leading capabilities. "This is an incredibly exciting time for Willis Towers Watson," said Samaroo. "We see

      11/30/21 1:12:37 PM ET
      $WLTW
      Specialty Insurers
      Finance
    • Willis Towers Watson Announces Changes with Respect to the Board of Directors

      Appointment of Four New Directors Supported by Elliott Management to Oversee Execution of the Company's New Strategic Plan New Board-Level Committee to Help Oversee the Company's Operational Transformation Plan DUBLIN, Ireland, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Willis Towers Watson (the "Company") is pleased to announce that it has selected Inga Beale, Fumbi Chima, Michael Hammond, and Michelle (Shelly) Swanback to join its Board of Directors. As previously announced, the Company had been engaging in a thorough, multi-year succession planning process prior to announcing the transaction with Aon in March 2020, including planning with respect to the composition of the Board. Today's announ

      11/18/21 9:00:00 AM ET
      $WLTW
      Specialty Insurers
      Finance

    $HZNP
    $WLTW
    SEC Filings

    See more
    • SEC Form 15-12G filed by Horizon Therapeutics Public Limited Company

      15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)

      10/16/23 4:44:27 PM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Horizon Therapeutics Public Limited Company

      S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)

      10/6/23 4:30:58 PM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Horizon Therapeutics Public Limited Company

      S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)

      10/6/23 4:28:57 PM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HZNP
    $WLTW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Horizon Pharma with a new price target

      H.C. Wainwright initiated coverage of Horizon Pharma with a rating of Neutral and set a new price target of $74.00

      11/1/22 7:30:31 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Horizon Pharma downgraded by SVB Leerink

      SVB Leerink downgraded Horizon Pharma from Outperform to Mkt Perform

      8/4/22 7:17:35 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Horizon Pharma with a new price target

      UBS initiated coverage of Horizon Pharma with a rating of Buy and set a new price target of $139.00

      6/14/22 7:20:43 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HZNP
    $WLTW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Watkins Thomas returned $20,550,600 worth of Ordinary Shares to the company (176,400 units at $116.50), closing all direct ownership in the company (SEC Form 4)

      4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)

      10/6/23 6:24:28 PM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mahony Susan returned $2,172,842 worth of Ordinary Shares to the company (18,651 units at $116.50), closing all direct ownership in the company (SEC Form 4)

      4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)

      10/6/23 6:22:58 PM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Witz Pascale returned $5,353,292 worth of Ordinary Shares to the company (45,951 units at $116.50), closing all direct ownership in the company (SEC Form 4)

      4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)

      10/6/23 6:21:24 PM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HZNP
    $WLTW
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $HZNP
    $WLTW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

      Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well

      2/19/25 9:00:00 AM ET
      $AVTE
      $DVAX
      $HZNP
      $MRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Rule 17(e) Announcement - Horizon Therapeutics plc

        NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the Scheme becoming effective Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that

      10/6/23 8:30:00 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rule 17(d) Announcement – Horizon Therapeutics plc

        NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the outcome of the Court Sanction Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that the Irish H

      10/5/23 7:40:00 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Horizon Therapeutics Public Limited Company (Amendment)

      SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)

      2/9/23 11:22:19 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Horizon Therapeutics Public Limited Company (Amendment)

      SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)

      2/9/23 11:18:36 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Horizon Therapeutics Public Limited Company (Amendment)

      SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)

      2/7/23 10:33:00 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HZNP
    $WLTW
    Financials

    Live finance-specific insights

    See more
    • Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre

      9/5/23 9:05:00 AM ET
      $HZNP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

      THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly see

      9/1/23 9:20:00 AM ET
      $AMGN
      $HZNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

      Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831157622/en/ As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern D

      9/1/23 9:20:00 AM ET
      $AMGN
      $HZNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations